Avanos Medical, Inc. (NYSE: AVNS), a leading medical technology company, today announced the appointment of David Pacitti as its new chief executive officer, effective April 14, 2025.

Abbott Laboratories' medical device business is executing well, with double-digit growth in structural heart and diabetes.

ABT's shares rise on the back of its diversified business portfolio. However, the unfavorable macroeconomic scenario is concerning.

Prior to joining Siemens Healthineers in 2015, Pacitti held several leadership roles at Abbott Vascular, including division vice president of U.S. commercial operations, sales and marketing.

Prior to joining Siemens Healthineers in 2015, Pacitti held several leadership roles at Abbott Vascular, including division vice president of U.S. commercial operations, sales and marketing ...

An update from Avanos Medical ( ($AVNS) ) is now available. On March 17, 2025, Avanos Medical announced the appointment of David Pacitti as its ...

Avanos Medical (NYSE:AVNS) announced today that it appointed David Pacitti as its new CEO, effective April 14, 2025.

Siemens Healthineers’ president of the Americas, David Pacitti, is leaving the imaging giant to become CEO of the devicemaker ...

In 2006, Abbott acquired Guidant, a leader in coronary and vascular products, and Kos Pharmaceuticals, a speciality pharma company with a significant lipid management portfolio. In 2009 ...

Teleflex management announced a significant acquisition and business split, but the market reacted negatively. Read why I remain neutral on TFX stock.

The optical imaging market is poised for steady growth, driven by technological advancements, increasing healthcare applications, and rising demand for precision diagnostics. With an anticipated CAGR ...